HNN3.0

Project cooperationUpdated on 12 January 2026

Mass Spetrometry Metabolomics: Bioactive Metabolites and Host-Microbiota Interactions

Research group leader at Institute of Microbiology Czech Acad Sci

Praha, Czech Republic

About

We offer advanced targeted and untargeted mass spectrometry–based metabolomics built around state-of-the-art UHPLC–high-resolution mass spectrometry with ion mobility separation (timsTOF HT, Bruker). Our platform enables comprehensive, high-sensitivity profiling of low-molecular-weight metabolites across complex biological matrices, supporting research on bioactive metabolites, microbial metabolism, and host–microbiota interactions.

Our expertise covers the complete metabolomics workflow, including standardized sample preparation and analysis of microbial cultures, cell lysates, and host-derived samples such as mouse and human feces, serum, and urine. We apply complementary chromatographic strategies (reverse-phase, HILIC, and derivatization-based methods) to maximize metabolome coverage. Data analysis integrates commercail, open-source, and in-house software and resources, covering tools for chemical space visualization and metadata mapping, metabolite annotation with large spectral libraries and in silico tools, statistical approaches for cohort-level comparisons and biomarker discovery, and repository-scale data exploration.

A key strength is the tight integration of metabolomics with biosynthesis, genome mining, and functional interpretation. We link metabolomic profiles to microbial gene clusters, metabolic pathways, and biological activity using differential metabolomics, stable isotope labeling, and genetic and biochemical validation. Our research includes discovery and characterization of novel bioactive microbial metabolites, with relevance to antimicrobial resistance and host–microbe communication, supported by unique gnotobiotic animal models.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Type

  • Partner seeks Consortium/Coordinator

Organisation

Institute of Microbiology Czech Acad Sci

R&D Institution

Praha, Czech Republic

Similar opportunities

  • Project cooperation

    Advancing Horizon Europe projects through microbiota and metabolomics for translational and clinical research

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Silvia Angeletti

    Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • Project cooperation

    Saliva-based metabolomics platform & expertise for Horizon research and innovation projects

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Dr Christopher Wall

    cofounder/CSO at Maven Health

    Zurich, Switzerland

  • Project cooperation

    Microbiome, Multi-Omics, and Drosophila Models for Sex/Gender-Aware Precision Prevention in Cardiometabolic and Brain Health

    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches

    Jordi Mayneris Perxachs

    Group Leader - R4 at GIRONA BIOMEDICAL RESEARCH CENTRE (IDIBGI)

    Girona, Spain